Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.

Oncotarget - 16 Feb 2016

Leitch Calum, Osdal Tereza, Andresen Vibeke, Molland Maren, Kristiansen Silje, Nguyen Xuan Nhi, Bruserud Øystein, Gjertsen Bjørn Tore, McCormack Emmet

Abstract excerpt

Palliative care in acute myeloid leukaemia (AML) is inadequate. For elderly patients, unfit for intensive chemotherapy, median survival is 2-3 months. As such, there is urgent demand for low-toxic palliative alternatives. We have repositioned two commonly administered anti-leukaemia drugs, valproic acid (VPA) and hydroxyurea (HU), as a combination therapy in AML. The anti-leukemic effect of VPA and HU was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorescent Antibody Technique

Share to Hydroxyurea

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Valproic Acid

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26812881
DOI: 10.18632/oncotarget.6991
PMCID: PMC4884979

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.PMID 26812881Read ↗

Pharmacological activation of the p53 pathway in haematological malignanciesSemantic proximity Read ↗

Nucleoside-based anticancer drugs: Mechanism of action and drug resistanceSemantic proximity Read ↗

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.Semantic proximity Read ↗

Could valproic acid be an effective anticancer agent? The evidence so farSemantic proximity Read ↗

Targeting mitochondria mitigates chemotherapy-induced bone marrow dysfunctionSemantic proximity Read ↗

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.Semantic proximity Read ↗

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair InhibitorsSemantic proximity Read ↗

Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.Semantic proximity Read ↗

Base-Modified Nucleosides as Chemotherapeutic Agents: Past and FutureSemantic proximity Read ↗

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of ResistanceSemantic proximity Read ↗

TP53 loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.